智翔金泰连亏5年 2023年上市募资34.7亿元

Group 1 - The company, Zhixiang Jintai, forecasts a significant increase in revenue for 2025, estimating between 209.45 million to 250.88 million yuan, representing a year-on-year growth of 595.96% to 733.62% [1] - The company anticipates a reduction in net loss for 2025, projecting a loss of between 480.64 million to 587.45 million yuan, which is a decrease of 20.98 million to 316.64 million yuan compared to the previous year, reflecting a year-on-year reduction of 26.32% to 39.71% [1] - The company's net profit attributable to shareholders from 2021 to 2024 has shown consistent losses, with figures of -322 million, -576 million, -801 million, and -797 million yuan respectively [1] Group 2 - Zhixiang Jintai was listed on the Shanghai Stock Exchange's Sci-Tech Innovation Board on June 20, 2023, with an initial public offering of 91.68 million shares at a price of 37.88 yuan per share [2] - The total amount raised from the IPO was 3.47 billion yuan, with a net amount of 3.29 billion yuan after deducting issuance costs, which was 688.60 million yuan less than the originally planned amount [2] - The company intended to raise 3.98 billion yuan for projects related to antibody industrialization and research, but the actual fundraising fell short of this target [2]